


**APC anti-mouse CD16.2 (FcγRIV)**

<b>Catalog # / Size:</b>	1347525 / 25 µg 1347530 / 100 µg
<b>Clone:</b>	9E9
<b>Isotype:</b>	Hamster IgG
<b>Immunogen:</b>	FCγR4 Åĉâ,–â€œEC domain fusion with IgG1 Fc
<b>Reactivity:</b>	Mouse
<b>Preparation:</b>	The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
<b>Formulation:</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Concentration:</b>	0.2



C57BL/6 bone marrow cells were stained with CD16.2 (clone 9E9) APC (filled histogram) or Armenian hamster IgG APC (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** Additional reported applications (for the relevant formats of this clone) include: blocking of FcγRIV function<sup>1</sup> and inhibition of immune complex binding<sup>1,2</sup>. The LEAF™ or Ultra-LEAF™ purified antibody (Endotoxin < EU/microg, Azide-Free, 0.2 µm filtered) is recommended for functional assays ([contact our custom solutions team](#)).

**Application References:** 1. Mancardi DA, *et al.* 2008. *J. Clin. Invest* 118:3738. (FC, Block)  
2. Nimmerjahn F, *et al.* 2005. *Immunity* 23:41.

**Description:** FcγRIV, also known as CD16.2, is an intermediate-affinity activating receptor for IgG2a and IgG2b. CD16.2 is the mouse homolog of human FcγRIIIA. CD16.2 is a low-affinity IgE receptor for all allotypes and the ligation of FcγRIV by antigen-IgE immune complexes promotes macrophage-mediated phagocytosis and is involved in lung inflammation.

**Antigen References:** 1. Mechetina LV, *et al.* 2002. *Immunogenetics* 54:463-8.  
2. Nimmerjahn F, *et al.* 2005. *Immunity* 23:41-51.  
3. Seeling M, *et al.* 2013. *Proc. Natl. Acad. Sci.* 110:10729.